Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: One year follow-up of omalizumab therapy

European Journal of Medical Research

Volumn 16, Issue 9, 2011, Pages 407-410

  Velling, Peter ^a   Skowasch, D ^b   Pabst, S ^b   Jansen, E ^b   Tuleta, I ^b   Grohe C ^a  

^a The Lungenklinik Berlin Buch   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Allergic asthma; Anti IgE; Atopic dermatitis; Omalizumab; Quality of life

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE; OMALIZUMAB; SALBUTAMOL; SALMETEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IMMUNOGLOBULIN E;

ADULT; ALLERGIC ASTHMA; ANAPHYLAXIS; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE REACTION; MALE; NAUSEA; OUTCOME ASSESSMENT; QUALITY OF LIFE; COMORBIDITY; PROSPECTIVE STUDY;

EID: 80053409220     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-16-9-407     Document Type: Article

References (14)

1. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S et al Low-dose anti-IgE in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2008 Nov;120(5):1223-1225.
2. Bieber T. Atopic dermatitis. N Engl J Med 2008 Apr;358(14):1483-94.
3. Bousquet J, Cabreba P, Berkman N. Buhl R, Holgate S, Wenzel S et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005 Mar;60 (3):302-308. (Pubitemid 40293345)
4. Finlay AY, Khan GK. Dermatology life quality Index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology 1994 May;19 (3):210-216. (Pubitemid 24194579)
5. Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Resp Med 2009 Aug;103(8):1098-1113.
6. Humbert M, Beasly R, Ayres J, Slavin R, Hebert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005 Mar;60(3):309-316. (Pubitemid 40293346)
7. Incorvaia C, Pravettoni C, Mauro M, Yacoub MR, Tarantini F, Riario-Sforza GG. Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis 2008 Jun;69(2):78-80.
8. Krathen RA, Hsu S. Failure of Omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005 Aug;35(2):338-340. (Pubitemid 40979597)
9. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with Omalizumab. J Am Acad Dermatol 2006 Jan;54(1):68-72. (Pubitemid 41832460)
10. Lim A, Luderschmidt S, Weidinger A, Schnopp C, Ring J, Hein R, Ollert M, Mempel M. The IgE repertoire in PBMCs of atopic patients is characterized by individual reaarangements without variable region of the heavy immunoglobulin chain bias. J Allergy Clin Immunol 2007 Sep;120(3):696-706, (Pubitemid 47334838)
11. Molimard M, De Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med. 2008 Jan; 102(1):71-76. (Pubitemid 350161845)
12. National Institutes of Health. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2007. Available from: http://www.ginaasthma.com
13. Sheinkopf LE, Rafi AW, Do LAT, Katz RM, Klaustermeyer WB. Efficacy of Omalizumab in the treatment of atopic dermatitis: A pilot study. Allergy and Asthma Proceedings 2008 Sep-Oct;29(5):530-537.
14. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006 Jul;5 (1): 168-170. (Pubitemid 43867028)